Second major clinical trial to select PharmAla Biotech as supplier since PharmAla become the first public company to manufacture GMP MDMA
VANCOUVER, August 31, 2022 (Canada Newswire) – PharmAla Biotech is proud to
have been selected as the MDMA manufacturing partner for the University of Sydney’s
upcoming Phase 2 Clinical Trial. Founded in 1850, The University of Sydney is one of
the top universities in Australia.
There is a high rate of comorbidity between alcohol use disorders and Post Traumatic
Stress Disorder which is associated with greater clinical impairment and poorer
prognosis. Led by Dr. Kirsten Morley, Principal Investigator, the trial will examine
whether MDMA can enhance outcomes for patients with these treatment resistant
“Australia is rapidly becoming one of the most exciting locations for MDMA research
anywhere in the world. I’m sure that the evidence gathered by Prof. Morley and the
University of Sydney team will add valuable data to this growing body of research,” said
Nick Kadysh, PharmAla’s CEO. “It’s also clear that PharmAla is rapidly becoming the
supplier of choice for clinical MDMA researchers worldwide; that our work can be used
to contribute to the scientific data surrounding this molecule.”
This is the second major Clinical Trial to select PharmAla as their MDMA supplier in
August alone. PharmAla’s LaNeo MDMA will be delivered to the University of Sydney in
2 tranches, with deliveries beginning in early 2023. The total contract value is
approximately $125,000 USD.
PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.
Nicholas Kadysh, CEO